After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Ideate-Lung02 goes on global clinical hold.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
The company is set to start a phase 2/3 trial this month.
